Comparison of efficacy of nadroparin and fondaparinux sodium for prevention of deep vein thromboembolism in lower extremities after total hip arthroplasty and total knee arthroplasty: a retrospective study of 592 patients

被引:0
|
作者
Gao, Xiang [1 ]
Jin, Xiaowei [1 ]
Huang, Rui [1 ]
Li, Zhenxing [1 ]
Zhang, Hanle [2 ]
Fan, Pei [1 ]
机构
[1] Wenzhou Med Univ, Yuying Childrens Hosp, Dept Orthoped, Affiliated Hosp 2, 109 Xueyuan West Rd, Wenzhou, Zhejiang, Peoples R China
[2] Wenzhou Med Univ, Yuying Childrens Hosp, Affiliated Hosp 2, Dept Rehabil, Wenzhou, Zhejiang, Peoples R China
关键词
Deep vein Thromboembolism; Nadroparin; Fondaparinux Sodium; Total hip arthroplasty; Total knee arthroplasty; VENOUS THROMBOEMBOLISM; ENOXAPARIN; PROPHYLAXIS; THROMBOSIS; SURGERY;
D O I
10.1186/s12893-024-02440-0
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objectives To compare the efficacy of nadroparin and fondaparinux sodium for prevention of deep vein thromboembolism (DVT) in lower extremities after total hip arthroplasty (THA) and total knee arthroplasty (TKA). Methods A total of 592 patients were enrolled in the study. Clinical data of patients who underwent total hip arthroplasty (THA) and total knee arthroplasty (TKA) in our hospital from December 2021 to September 2022 were retrospectively collected, which mainly included patients' general information, surgery-related information, and DVT-related information. The patients were categorized into the nadroparin group(n = 278) and the fondaparinux sodium group(n = 314) according to the types of anticoagulants used. Anticoagulant therapy began 12-24 h after operation and continued until discharge. DVT prevalence between two groups was compared. The Statistical Package for Social Sciences (SPSS) software version 25 (SPSS, Armonk, NY, USA) was used for statistical analysis. Results The prevalence of DVT in the nadroparin group and the fondaparinux sodium group was 8.3% (23/278) and 15.0% (47/314), respectively(p = 0.012). Statistical analysis showed that nadroparin group showed a lower prevalence of thrombosis than fondaparinux group (OR = 1.952, P = 0.012). Subgroup analyses showed that nadroparin group had a lower prevalence of DVT than fondaparinux group in some special patients groups such as female patients (OR = 2.258, P = 0.007), patients who are 65-79 years old (OR = 2.796, P = 0.004), patients with hypertension (OR = 2.237, P = 0.042), patients who underwent TKA (OR = 2.091, P = 0.011), and patients who underwent combined spinal-epidural anesthesia (OR = 2.490, P = 0.003) (P < 0.05). Conclusion Nadroparin may have an advantage over fondaparinux sodium in preventing DVT in lower extremities after THA and TKA.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Risk of Venous Thromboembolism after Total Knee Arthroplasty in Patients with Rheumatoid Arthritis
    Izumi, Masahiro
    Migita, Kiyoshi
    Nakamura, Mashio
    Jiuchi, Yuka
    Sakai, Tatsuya
    Yamaguchi, Takayuki
    Asahara, Tomihiko
    Nishino, Yuichiro
    Bito, Seiji
    Miyata, Shigeki
    Kumagai, Kenji
    Osaki, Makoto
    Mawatari, Masaaki
    Motokawa, Satoru
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (06) : 928 - 934
  • [42] Retrospective comparison of three thromboprophylaxis agents, edoxaban, fondaparinux, and enoxaparin, for preventing venous thromboembolism in total knee arthroplasty
    Hiroshi Sasaki
    Kazunari Ishida
    Nao Shibanuma
    Katsumasa Tei
    Hiroomi Tateishi
    Akihiko Toda
    Yukiko Yamashiro
    Tomoyuki Matsumoto
    Ryosuke Kuroda
    Masahiro Kurosaka
    International Orthopaedics, 2014, 38 : 525 - 529
  • [43] Retrospective comparison of three thromboprophylaxis agents, edoxaban, fondaparinux, and enoxaparin, for preventing venous thromboembolism in total knee arthroplasty
    Sasaki, Hiroshi
    Ishida, Kazunari
    Shibanuma, Nao
    Tei, Katsumasa
    Tateishi, Hiroomi
    Toda, Akihiko
    Yamashiro, Yukiko
    Matsumoto, Tomoyuki
    Kuroda, Ryosuke
    Kurosaka, Masahiro
    INTERNATIONAL ORTHOPAEDICS, 2014, 38 (03) : 525 - 529
  • [44] Manual calf massage and passive ankle motion reduce the incidence of deep vein thromboembolism after total hip arthroplasty
    Imai, Norio
    Ito, Tomoyuki
    Suda, Ken
    Miyasaka, Dai
    Endo, Naoto
    JOURNAL OF ORTHOPAEDIC SCIENCE, 2017, 22 (04) : 726 - 730
  • [45] Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban, Enoxaparin, or Aspirin for Thromboprophylaxis
    Lindquist, Desirae E.
    Stewart, David W.
    Brewster, Aaryn
    Waldroup, Caitlin
    Odle, Brian L.
    Burchette, Jessica E.
    El-Bazouni, Hadi
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2018, 24 (08) : 1315 - 1321
  • [46] Internal Validation of a Risk Scoring System for Venous Thromboembolism After Total hip or Knee Arthroplasty
    Akamine, Akihiko
    Takahira, Naonobu
    Kuroiwa, Masayuki
    Tomizawa, Atsushi
    Atsuda, Koichiro
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [47] Direct treatment comparison of DAbigatran and RIvaroxaban versus NAdroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery: design of a randomised pilot study (DARINA)
    van der Veen, Lucia
    van Raay, Jos J. A. M.
    Gerritsma-Bleeker, Carina L. E.
    Veeger, Nic J. G. M.
    van Hulst, Marinus
    BMJ OPEN, 2013, 3 (01):
  • [48] Efficacy and safety of rivaroxaban thromboprophylaxis after arthroplasty of the hip or knee: retrospective cohort study
    Loganathan, V.
    Hua, A.
    Patel, S.
    Gibbons, C.
    Vizcaychipi, M. P.
    ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND, 2016, 98 (07) : 507 - 515
  • [49] Internal Validation of a Risk Scoring System for Venous Thromboembolism After Total hip or Knee Arthroplasty
    Akamine, Akihiko
    Takahira, Naonobu
    Kuroiwa, Masayuki
    Tomizawa, Atsushi
    Atsuda, Koichiro
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [50] Psychosocial predictors for outcome after total joint arthroplasty: a prospective comparison of hip and knee arthroplasty
    Marion Lindner
    Olaf Nosseir
    Anett Keller-Pliessnig
    Per Teigelack
    Martin Teufel
    Sefik Tagay
    BMC Musculoskeletal Disorders, 19